Supernus Pharmaceuticals reported $127.81M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.


Gross Profit On Sales Change Date
Abbott USD 5.87B 50M Jun/2025
ANI Pharmaceuticals USD 113.48M 10.61M Jun/2025
Aurora Cannabis CAD 27.95M 18.6M Jun/2025
Bristol-Myers Squibb USD 8.9B 714M Jun/2025
Canopy Growth CAD 18.04M 6.06M Jun/2025
Corcept Therapeutics USD 191M 36.19M Jun/2025
Eisai JPY 160.05B 12.42B Jun/2025
Eli Lilly USD 13.11B 2.61B Jun/2025
Novo Nordisk 64.01B 1.19B Jun/2025
Pacira USD 125.91M 8.71M Jun/2025
Perrigo USD 362.9M 29.4M Jun/2025
Pfizer USD 10.88B 248M Jun/2025
Supernus Pharmaceuticals USD 127.81M 6.25M Jun/2025
United Therapeutics USD 711M 9.1M Jun/2025
Xeris Pharmaceuticals USD 59.64M 9.02M Jun/2025